Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses RNAi Patent Family to Qiagen

NEW YORK, Sept. 21 (GenomeWeb News) - Qiagen has licensed a number of RNA interference patents from Alnylam Pharmaceuticals, Alnylam said today.

 

Under the non-exclusive license, Qiagen will be allowed to provide research products and services using RNAi under the Kreutzer-Limmer patent family, which covers small interfering RNAs and their use to mediate RNAi in mammalian cells.

 

Qiagen already offers siRNA libraries and high-throughput siRNA synthesis technology.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.